Taipei Veterans General Hospital and the German BioNTech biotechnology company jointly cooperate in the research and development of new drugs. This (17) morning, Superintendent Wei-Ming Chen of Taipei VGH and Mr. Sean Marettia, Chief Commercial and Chief Business Officer of BioNTech biotechnology company, signed a memorandum of cooperation on behalf of the two parties, injecting a new force into Taiwan's cancer precision medicine.
Superintendent Wei-Ming Chen said that the Taipei Veterans General Hospital will continue to be in line with international standards, explore the most advanced medical technology, bring more innovations to Taiwan's medical care, and continue to work tirelessly for the health of the people in Taiwan. We also work tirelessly for the health of the Taiwan people. Conquering Cancer Together and Collaborate for impact.
Chief Commercial and Chief Business Officer Mr. Sean Marettia is very happy to have this opportunity to cooperate with Taiwan's top medical center. He was deeply impressed by the Taipei Veterans General Hospital’s outpatient chemotherapy, integrated Traditional Chinese medicine and Western therapy, and the world's most advanced heavy ion cancer therapy center.
In the field of cancer treatment, Taipei Veterans General Hospital has reached the world-class level in terms of medical technology and treatment effects. Up to one-third of the inpatients in the hospital are cancer patients. In addition to advanced surgical operations and medical treatment, In May 2023, the world's most advanced heavy ion cancer therapy center was opened to give full play to the power of interdisciplinary team treatment, and the results are exciting. Precision and personalized medicine are the international trends in cancer treatment. Based on the spirit of pursuing excellence, Taipei Veterans General Hospital cooperates with German BioNTech this time to strive for more new treatment options for Taiwan’s people.
Last Modified：2023/08/18 09:25:07